

Synthesis, inhibitory and activation properties of prenyldiphosphate mimics for aromatic prenylations with *ubiA*-prenyltransferase

Svetlana Zakharova, Michael Fulhorst, Lech Łuczak, and Ludger Wessjohann*

Department of Bio-organic Chemistry, Leibniz-Institute of Plant Biochemistry
Weinberg 3, D-06120 Halle (Saale), Germany
E-mail: wessjohann@ipb-halle.de

Dedicated to Prof. Dr. Karsten Krohn on the occasion of his 60th birthday
(received 01 Jul 04; accepted 30 Nov 04; published on the web 07 Dec 04)

Abstract


4-Hydroxybenzoate oligoprenyl transferase from *E. coli* (*ubiA*-prenyl transferase) is a crucial enzyme for ubiquinone biosynthesis. It catalyzes the formation of 3-oligoprenyl-4-hydroxybenzoates like geranyl hydroxybenzoate (GHB, **23**) from geranyl pyrophosphate (GPP, **22**). Several analogues and mimics of geranyl pyrophosphate have been prepared for an examination of their ability to inhibit the enzyme. 7,11-Dimethyl-3-oxododeca-6,10-dienoic acid (**2**), 3-hydroxy-7,11-dimethyldodeca-6,10-dienoic acid (**3**), 2-hydroxy-4,8-dimethyl-3,7-nonadienylphosphonic acid (**4**), and tripotassium [[(4*E*)-5,9-dimethyldeca-4,8-dienyl]phosphinato](difluoro)methylphosphonate (**5**) were synthesized from geraniol. ω -2, ω -1-Dihydroxylated farnesyl diphosphate **6** was prepared from *trans,trans*-farnesol. All compounds were tested for enzyme inhibition in a competitive assay with natural substrate. The effect of these compounds on *ubiA*-prenyltransferase activity varied substantially, ranging from almost full inhibition to, surprisingly, enhanced enzymatic activity at low concentrations by some compounds. A special, EDTA-modifiable magnesium effect is discussed as potential reason.

Keywords: Prenyltransferase, geranyl diphosphate, enzyme inhibition, farnesyl transferase inhibitor, enzyme activation, magnesium ion effect

Introduction

Prenyl transferases catalyze the electrophilic alkylation of electron-rich acceptor substrates by the hydrocarbon moiety of allylic isoprenoid diphosphates.¹ Some of the more common acceptors are carbon-carbon double bonds (synthesis of isoprenoid chains), aromatic rings (e.g. for the synthesis of respiratory quinones, vitamins E),² amino groups (modification of tRNAs),³ and sulfhydryl moieties (modification of proteins such as *ras*-farnesyl transferase, an *anti*-

proliferation target).⁴ The products of prenyl transfer reactions are ultimately converted into over 30000 naturally occurring isoprenoid compounds. Isoprenoid biosynthesis is essential in all organisms. In *Escherichia coli*, for instance, the isoprenoids ubiquinone and bactoprenol are required for respiration and cell wall biosynthesis, respectively. The aromatic polyprenyl transferase encoded by *ubiA* is involved in the biosynthesis of prenylated quinones (Scheme 1).⁵ *In vivo*, the enzyme transfers diphosphorylated acyclic oligoprenyl moieties (diphosphorylated terpene alcohols) to the *meta*-position of 4-hydroxybenzoic acid (PHB).⁶



Scheme 1. Biosynthesis of ubiquinones in *E. coli*. (similar in other organisms).

Possible candidates for mimics of geranyl diphosphate should fulfill three requirements: they should show affinity to a prenyl diphosphate synthase or transferase; they should be stable under study conditions, especially against hydrolysis; and they should be easy to synthesize. With these requirements in mind, we approached two different classes of candidates for our approach. The first class consists of non-hydrolysable diphosphate analogues with phosphorus-based acidic moieties, the second one of mimics where all phosphates are replaced by non-phosphorus (acidic) moieties.

A natural example of the latter group is chaetomelic acid (**1**, Figure 1), which was isolated from the coelomycete *Chaetomella acutisetata*. It inhibits farnesyl-protein-transferase at IC50-values in the nanomolar range.⁷ Chaetomelic acid is a competitor to farnesyl pyrophosphate (FPP), and does not contain any phosphate moiety.




Figure 1. Chaetomelic acid A (**1**), a natural inhibitor of farnesyl-protein transferase.

We were interested in the synthesis of the similar β -keto acid **2** and β -hydroxy acid **3** which might act as competitive inhibitors of *ubiA*-*p*-hydroxybenzoate oligoprenyl transferase (Figure 2).

As examples of the first class, several non-hydrolysable allylic diphosphate mimics are known from the literature. These include phosphonophosphates,⁸ phosphonophosphinates,⁹ and diphosphonates,¹⁰ where the methylene group replaces the oxygen between phosphorus and

carbon and the bridging oxygen between the two phosphorus atoms. All these phosphinates are inhibitors, but the bisphosphonates with an ester bond linked to prenyl are still enzyme cleavable and thus potential substrates.^{6b,11,12} Therefore, we excluded the latter and decided to try β -hydroxyphosphonic acid **4** as an inhibitor halfway between class I and class II. Such compounds were investigated by Kang et al. with respect to their inhibitory activity of protein farnesyltransferase.¹³ A pure class II substrate is the stable diphosphate analog **5**. Finally, 10,11-dihydroxy-3,7,11-trimethyldodeca-2,6-dienyl diphosphate (**6**), i.e. oxidized FPP, was included. Although it is a hydrolysable substrate in principle, we knew from earlier experiments that it is accepted poorly by *ubiA*-transferase and thus, it may act as an inhibitor. In this report, we present the synthesis of these compounds, along with a study of their impact on the magnesium depended activity of aromatic *ubiA*-oligoprenyl transferase of *E. coli*.





Figure 2. Potential inhibitors of prenyl transferase.

Results and Discussion


Syntheses

The synthesis of the β -keto acid **2** and β -hydroxy acid **3** is shown in Scheme 2. Methyl acetoacetate was selectively alkylated at position 4 with geranyl bromide. Treatment of the resulting β -keto ester **7** with LiOH in THF/H₂O gave the desired alkylated β -carboxylic acid **2**. Reduction of ketone **7** with NaBH₄ in MeOH produced β -hydroxy ester **8**, which upon hydrolysis with LiOH in THF/H₂O afforded the racemic β -hydroxy acid **3**.




Scheme 2. Synthesis of geranyl-based β -keto carboxylic acid **2** and β -hydroxy carboxylic acid **3**.

The synthesis of the geranyl-based phosphonate **4** (Scheme 3) started with the Doering oxidation of geraniol to geranial (**9**), which was reacted with dimethyl methylphosphonate anion to give racemic **10**. This methyl phosphonic ester was cleaved with trimethylsilyl bromide in the presence of 2,4,6-collidine as acid scavenger to afford the free hydroxyphosphonic acid **4**.^{14,15} An attempt to oxidize β -hydroxy phosphonate **3** to the β -keto phosphonate by Doering oxidation failed.




Scheme 3. Synthesis of geranyl-based β -hydroxy phosphonic acid **4**.

The synthetic route to phosphonate **5** (Scheme 4), a hydrolytically stable analog of diphosphates, was identical to one known for a farnesyl derivative.¹⁴ The difluoromethylene link is a better oxygen mimic than methylene. Thus, geraniol was subjected to a standard C₂-homologation to form ester **11**, followed by ester reduction and conversion of the resulting alcohol into bromide **12**. The Arbuzov reaction¹⁶ of **12** with excess of triethyl phosphate delivered in high yield diester **13**, which by base-induced hydrolysis was converted into the mono acid. Subsequent DMF-catalyzed reaction with oxalyl chloride in benzene at room temperature afforded ethyl phosphonochloridoate **14**. Treatment of the intermediate mono phosphonate with excess *N,N*-dimethylaminotrimethylsilane in dichloromethane prior to acid chloride formation resulted in a faster reaction and a cleaner transformation into ethyl phosphonochloridoate **14**.^{14,17} Subsequent C-P coupling reaction was performed by dropwise addition of a THF solution of **14** to a solution of the anion **15** at -78 °C. The anion **15** was formed by the reaction of LDA with diethyl difluoromethylphosphonate.¹⁸ The resulting diester **16** was cleaved with TMS-I in the presence of 2,4,6-collidine as acid scavenger¹⁴ to produce the desired product **5**.




Scheme 4. Synthesis of tripotassium phosphinato(difluoro)methylphosphonate **5**.



Scheme 5. Synthesis of (*E,E*)-10,11-dihydroxyfarnesyl diphosphate **6**.

The synthesis of (*E,E*)-10,11-dihydroxyfarnesyl diphosphate started from all-*trans* farnesol (Scheme 5), protected as acetate **17**. For selective epoxidation of the 10,11-double bond we followed a method developed by van Tamelen et al.¹⁹ Farnesyl acetate was treated with NBS in aqueous *tert*-butyl alcohol²⁰ or aqueous 1,2-dimethoxyethane²¹ to give the desired bromohydrin **18** in 29% and 90% yield, respectively. Base induced the formation of epoxide **19**,²¹ which in turn, was ring-opened with aqueous perchloric acid to give triol **20**.²² (*E,E*)-10,11-Dihydroxyfarnesol **20** was converted into chloride **21**, which was finally transformed into (*E,E*)-10,11-dihydroxyfarnesyl diphosphate according to Davisson et al.²³



Scheme 6. Chemoenzymatic synthesis of geranyl hydroxybenzoate (GHB, **23**).

UbiA-Transferase inhibition

The compounds described above were tested for their ability to inhibit *ubiA*-transferase using a membrane fraction of a cell disruption of the *E. coli* K12 strain pALMU3.²⁴ Compounds were assayed in competition to 1 mM geranyl diphosphate (GPP) at concentrations ranging up to 1 mM (Scheme 6). These results, expressed as the geranyl hydroxybenzoate (GHB) formation in the presence of the compound divided by the GHB formation in the absence of the compound (i.e. relative conversions) are shown in Figures 3 and 4.




Figure 3. GHB synthesis from geranyl diphosphate as a function of inhibitor concentration: β -keto acid **2** (■)* and β -hydroxy acid **3** (●), phosphinato(difluoro)methylphosphonate **5** (▲), (*E,E*)-10,11-dihydroxyfarnesyl diphosphate **6** (▼).

* In this assay, the membrane fraction contained 32 mg protein/mL, all others contained 0.67 mg protein/mL. For standard assay conditions see Experimental Section.

Only β -hydroxy acid **3** and β -keto acid **2** showed significant inhibitory activity regarding the conversion of geranyl diphosphate (Figure 3).²⁵ Their IC₅₀ values are 0.36 and 0.58 mM, respectively. At 1 mM concentration, β -hydroxy carboxylate **3** showed almost complete inhibition of *ubiA*-transferase activity. β -Hydroxy phosphonate (from **4**, remaining activity: 90% at 1 mM, data not shown) and difluoro phosphinophosphonate **5** did not show significant inhibitory activity. Although these molecules are structurally more related to the natural substrate than the carboxylic acids, the lower binding affinities have been attributed to differences in the p*K*_a of the phosphate versus the phosphonate groups.²⁶ Difluoromethylene analogues more closely match the p*K*_a, but the fluorine atoms introduce steric interactions and other properties not found in the natural diphosphate substrates.²⁶ Another reason for the low activity of **4** and **5** might be the structural difference compared to the natural substrates because in **4** the distance of the diphosphate mimicking moiety to the first double bond is shorter, in **5** it is longer by one atom than in natural oligoprenyl diphosphates.

(*E,E*)-10,11-Dihydroxyfarnesyl diphosphate **6** is only very poorly accepted as substrate, although sterically it must be acceptable to the enzyme as has been shown by us before in a substrate model.¹² Surprisingly, under standard conditions as described above, its inhibitory effect is very weak too.

An interesting pattern was seen for inhibitors **3** and **5**. Before exerting inhibitory activity, their addition initially leads to enhanced conversion, i.e. they act as activators. This effect is dependent on the concentration not only of the inhibitor but also of the enzyme concentration (Figure 4). β -Hydroxy acid **3** is a potent inhibitor with a biocatalyst membrane fraction containing 0.67 mg protein/mL. After an initial 10% increase in activity at 0.05 mM concentration (vide infra) inhibitory properties prevail and at 1 mM concentration of **3**, enzyme activity is almost 0%. In the case of compound **5** the activation effect is even larger and up to 47% increase of activity at 0.1 mM concentration is observed at low enzyme concentration.




Figure 4. GHB synthesis from geranyl diphosphate as a function of inhibitor and enzyme concentration. The results for β -hydroxy carboxylate **3** (\blacksquare , \square) and for phosphinato(difluoro)-methylphosphonate **5** (\blacktriangle , \triangle) are shown with squares and triangles, respectively. Empty data points \square , \triangle : the membrane fraction contained 0.67 mg protein/mL; filled data points \blacksquare , \blacktriangle : the membrane fraction contained 2.68 mg protein/mL. For standard assay conditions see Experimental Section.

From our earlier experiments we know that even a small reduction in the concentration of the magnesium ions results in an increase of product formation (through enhanced enzyme stability).^{6b,27} Although elevated concentrations of magnesium ions ensure a high initial rate of the enzymatic reaction, they cause the enzyme denaturation much faster than in experiments where the MgCl_2 concentration is reduced. Thus, high salt concentration ultimately results in lower turnover. We suppose that the dual role played by MgCl_2 is particularly responsible for the increased enzymatic activity observed with small amounts of inhibitor. Because the tested inhibitors are diphosphate mimics, they are also able to form complexes with Mg^{2+} -ions. Due to

this complexation, especially with phosphinato(difluoro)methylphosphonate **5**, an activity increase up to 47% was observed. In order to prove this hypothesis, an alternative Mg^{2+} -scavenger, which should not have any inhibitory activity, was applied to the system. Indeed, experiments with ethylenediaminetetraacetic acid (EDTA) led to an enhancement of activity, similar in concentration dependence as observed before, but without any inhibition of the enzyme at higher concentrations (Figure 5).




Figure 5. GHB synthesis from geranyl diphosphate as a function of EDTA concentration (Mg^{2+} -complex formation). □: Membrane fraction with 0.67 mg protein/mL; ■: membrane fraction with 2.68 mg protein/mL. For standard assay conditions see Experimental Section.

Of course, such an effect is more evident at low enzyme concentration, i.e. in systems where the Mg^{2+} -concentration relative to that of the enzyme is high; thus $[Mg]^{2+}$ reduction results in a higher effect. Thus, the different activation/inhibition profiles of the compounds **2–6**, displayed e.g. in Figure 3, result from an overlap of several contrasting effects: a competitive inhibition at the enzyme, the magnesium ion binding properties of inhibitor vs. GPP vs. enzyme, and a resultant irreversible influence on a (concentration dependent) enzymatic activity.

In summary, the different substances described show varied effects on *ubiA*-transferase. For all compounds, a very slightly to significantly increased enzymatic activity was observed at low concentration. This can be attributed to the Mg^{2+} -complexating activity inherent to diphosphate mimics. At higher concentrations this positive effect is overruled by the inhibitory activity. The two best inhibitors were the β -oxidized carboxylic acids **2** and **3**, the latter is clearly superior. β -Keto acids like **2** may act in their enol form and thus may also be considered as β -hydroxy

carboxylates, although with less degree of freedom. These observations guide the way to improved inhibitors in the future.

Experimental Section

General Procedures. ^1H and ^{13}C NMR spectra were recorded on a Varian Mercury 300 and a Varian Mercury 400 instrument using CDCl_3 as a solvent (unless noted otherwise) and $(\text{CH}_3)_4\text{Si}$ or CDCl_3 (^{13}C , δ 77.00) as internal standards. ^{31}P and ^{19}F NMR spectra were recorded on a Varian Mercury 400. ^{31}P Chemical shifts are reported in ppm relative to an external standard of 85% H_3PO_4 . Non-quantitative measurements were performed in the hydrogen decoupled modus; quantitative measurements were performed in the hydrogen-coupled modus. A known volume of an aqueous solution of diammonium phenylphosphonate (1.0 M) was added to the samples as a quantitative internal standard. ^{19}F data were obtained using CFCl_3 as an external reference. Ion electrospray ionization (ESI) mass spectra were recorded on a Finnigan MAT TSQ 7000 or with a API 150Ex (Applied Biosystems) equipped with a turbo ionspray source. High-resolution ESI mass spectra were recorded on a Bruker 70e FT-ICR (Bruker Daltonics, USA) using nitrogen as drying gas at 150 °C. IR spectra were measured on a Bruker IFS 28 as thin oil films between KCl plates or as KBr pellets. HPLC was performed on a HP 1090 with integrated photo diode array detector (Multisphere 100-5 μm RP 18) or a Merck D-7000 (Lichrosphere 100-5 μm RP 18). Samples were chromatographed with methanol/water mixtures containing 0.2% formic acid 80:20, flow rate: 1 mL/min.

Tetrahydrofuran and diethyl ether were freshly distilled from sodium/benzophenone, dichloromethane was freshly distilled from calcium hydride. Other solvents and chemicals obtained from commercial sources were used without further purification. All moisture and air sensitive reactions were conducted under argon in vacuum-dried glassware. Flash column chromatography was carried out on silica [Merck: Kieselgel 60, particle size 0.040–0.063 mm (230–240 Mesh ASTM), Art.-No. 9385, Baker: silica for flash chromatography, particle size 0.030–0.060 mm, Art.-No. 7024-02] under a pressure of 1.4–1.6 bar. Thinlayer-chromatography was performed using silica plates from Merck (Kieselgel-60 F_{254} on aluminum sheets with fluorescence indicator, Prod.-No. 5554).

(6E)-7,11-Dimethyl-3-oxododeca-6,10-dienoic acid (2).²⁸ To a solution of ester **7** (0.5 g, 1.9 mmol) in THF/ H_2O (3:1, 4 mL) was added lithium hydroxide (0.42 g, 9.9 mmol), and the mixture was stirred over night at room temperature, acidified with 1 M hydrochloric acid and then extracted with ether (50 mL). The organic layer was washed with water (2 x 30 mL) and brine (30 mL), dried (Na_2SO_4) and concentrated to give **2** (0.31 g, 66%) as a yellow oil. ^1H NMR (300 MHz, CDCl_3): δ 5.07 (dd, J = 1.1, 6.9 Hz, 2H), 3.76–3.72 (m, 2H), 3.53–3.45 (m, 2H), 2.56–2.44 (m, 1H), 2.33–2.14 (m, 2H), 2.03–2.94 (m, 2H), 1.88–1.83 (m, 1H), 1.67 (s, 3H), 1.59 (s, 3H), 1.56 (s, 3H); ^{13}C NMR (75.5 MHz, CDCl_3): δ 208.7, 167.4, 136.7, 136.2, 123.9, 121.8,

49.1, 43.1, 39.6, 26.6, 25.7, 22.2, 17.7, 16.1. MS (APCI) (negative mode): m/z 237 $[M-H]^-$. IR (film): $\tilde{\nu}$ 3446 (bs), 2966, 2925, 2856 (sh), 1743, 1717, 1437, 1375, 1319, 1237, 1158, 1118 cm^{-1} .

(6E)-3-Hydroxy-7,11-dimethyldodeca-6,10-dienoic acid (3). To a solution of ester **8** (0.29 g, 1.1 mmol) in THF/H₂O (2:1, 3 mL) was added lithium hydroxide (92 mg, 2.2 mmol). After stirring at room temperature for 2 h were added ether (50 mL) and 1 M hydrochloric acid (30 mL). The organic layer was separated, washed with H₂O (30 mL), dried (Na₂SO₄) and concentrated to give carboxylic acid **3** (0.16 g, 59%) as a pale yellow oil. ¹H NMR (300 MHz, CDCl₃): δ 5.78 (bs, OH), 5.16–5.05 (m, 2H), 4.06–4.01 (m, 1H), 2.57 (dd, $J = 3.3, 16.5$ Hz, 1H), 2.47 (dd, $J = 8.8, 16.5$ Hz, 1H), 2.13–1.97 (m, 6H), 1.68 (s, 3H), 1.62 (s, 3H), 1.60 (s, 3H), ν 1.55–1.43 (m, 2H); ¹³C NMR (75.5 MHz, CDCl₃): δ 177.0, 135.9, 131.2, 124.1, 123.5, 67.6, 41.1, 39.7, 36.4, 26.4, 25.8, 24.2, 17.8, 16.1. MS (ESI): m/z (negative mode) 239 $[M-H]^-$. IR (film): $\tilde{\nu}$ 3419 (bs), 2966, 2924, 2857 (bs), 1716 (s), 1436, 1375, 1297, 1182, 1105, 1069, 983 (sh) cm^{-1} . Anal. Calcd for C₁₄H₂₄O₃: C, 69.96; H, 10.07. Found: C, 69.98; H, 10.27.

(3E)-2-Hydroxy-4,8-dimethylnona-3,7-dienylphosphonic acid (4). To a solution of phosphonate **10** (0.61 g, 2.3 mmol) and 2,4,6-collidine (0.84 mL, 6.5 mmol) in dichloromethane (20 mL) at 0 °C was added TMSBr (0.84 mL, 6.5 mmol) via syringe. After stirring at 0 °C for 30 min, the cooling bath was removed and stirring was continued for 6 h. Then the reaction was quenched by addition of 2 N hydrochloric acid (10 mL). The aqueous phase was extracted with ether (2 x 20 mL) and the organic layers were combined. The organic phase was washed with 2 N hydrochloric acid (2 x 10 mL), water (10 mL) and brine (10 mL), dried (Na₂SO₄) and concentrated to yield **4** (0.54 g, 99%) as a white solid. ¹H NMR (300 MHz, D₂O): δ 5.46–5.44 (m, 1H), 5.03–5.00 (m, 1H), 3.79 (s, 1H), 2.21–2.13 (m, 1H), 1.95–1.76 (m, 3H), 1.51 (s, 3H), 1.49 (s, 3H), 1.42 (s, 3H); ¹³C NMR (75 MHz, D₂O): δ 140.1, 134.4, 128.4, 125.0, 65.8, 39.6, 25.9, 21.9, 18.0, 16.8. MS (ESI) (negative mode): m/z 247 $[M-H]^-$; MS (HR) calculated for C₁₁H₂₁O₄P⁻ ($[M-H]^-$): 247.10992; found: 247.11046.

Tripotassium [(4E)-5,9-dimethyldeca-4,8-dienyl]phosphinato(difluoro)methylphosphonate (5). To a solution of **16** (0.24 g, 0.54 mmol) in dry dichloromethane (3 mL) under argon were added 2,4,6-collidine (0.24 mL, 1.82 mmol) followed by iodotrimethylsilane (0.50 mL, 3.81 mmol) at 0 °C drop-wise over 5 min. The reaction was stirred at 0 °C for 3 h, the solvent was evaporated and the residue was evacuated under vacuum. Aqueous 2 M KOH (2 mL) was added, and the resulting solution was extracted with ether (3 x 5 mL). The aqueous phase was freeze-dried and the organic compound was extracted with methanol (3 x 5 mL). The solvent was evaporated to produce **5** (0.14 g, 78%) as a white, amorphous powder. ¹H NMR (300 MHz, D₂O): δ 5.32–5.18 (m, 2H), 2.18–2.02 (m, 6H), 1.88–1.73 (m, 2H), 1.69 (s, 3H), 1.66–1.54 (m, 2H), 1.63 (s, 6H); ¹³C NMR (75.5 MHz, D₂O): δ 137.9, 134.5, 125.4, 125.3, 122.8 (tdd, not all signals were found), 39.95, 30.4 (d, $J = 15.1$ Hz), 28.3 (d, $J = 94.4$ Hz), 26.9, 25.9, 22.1 (d, $J = 5.3$ Hz), 18.1, 16.5; ³¹P (161.9 MHz, D₂O): δ 34.3 (td, $J = 46.5, 76.4$ Hz), 4.8 (td, $J = 46.5, 73.6$ Hz); ¹⁹F (376.3 MHz, D₂O): δ -121.4 (dd, $J = 73.6, 76.4$ Hz). MS (ESI): m/z (negative mode) 359 $[M-H]^-$; MS (HR) calculated for C₁₃H₂₃F₂O₂₃P₂ ($[M-H]^-$): 359.0994; found: 359.1004.

Ammonium (2*E*,6*E*)-10,11-dihydroxy-3,7,11-trimethyldodeca-2,6-dienyl diphosphate (6). A solution of chloride **21** (0.16 g, 0.57 mmol) in acetonitrile (2 mL) was treated with a solution of tri-(tetrabutylammonium) hydrogen diphosphate (1.03 g, 1.15 mmol) in acetonitrile (1.5 mL). After stirring at room temperature for 2 h, the solvent was removed by rotary evaporation, and the residue was dissolved in isopropyl alcohol / 25 mM ammonium bicarbonate (ion-exchange buffer) (1:49; v/v). The slightly yellow solution was slowly passed through a column containing 30 equiv of DOWEX AG 50W-X8 cation-exchange resin (ammonium form, 100–200 mesh) that had been equilibrated before with 2 column volumes of ion-exchange buffer. The column was eluted with 2 column volumes of the same buffer at a flow rate of 1 column volume/15 min. The eluent was lyophilized to dryness to yield a fluffy white solid **6** (0.37 g, max. 0.57 mmol) containing residual ammonium carbonate buffer. The organic diphosphate content was determined by quantitative ^{31}P NMR vs. ammonium phenylphosphonate as quantitative internal standard.^{12,18} ^1H NMR (300 MHz, D_2O): δ 5.43 (t, $J = 6.6$ Hz, 1H), 5.23 (t, $J = 6.3$ Hz, 1H), 4.44 (t, $J = 6.6$ Hz, 2H), 3.29 (d, $J = 9.3$ Hz, 1H), 2.23–1.95 (m, 6H), 1.69 (s, 3H), 1.59 (s, 3H), 1.39–1.03 (m, 2H), 1.12 (s, 6H); ^{13}C NMR (75.5 MHz, D_2O): δ 143.6, 136.9, 125.4, 120.6, 78.2, 74.4, 63.5 (d, $J = 4.5$ Hz), 39.8, 36.8, 29.9, 26.6, 25.2, 24.4, 16.7, 16.2; ^{31}P NMR (166 MHz, D_2O): δ – 5.8 (d, $J = 21.6$ Hz), –9.4 (d, $J = 21.6$ Hz). MS (HR) calculated for $\text{C}_{15}\text{H}_{29}\text{O}_9\text{P}_2^-$ ([M–H] $^-$): 415.12868; found 415.12922.

Methyl (6*E*)-7,11-dimethyl-3-oxododeca-6,10-dienoate (7). A suspension of NaH (0.75g, 60% suspension in mineral oil, 18.7 mmol) in THF (50 mL) was cooled to 0 °C, and a solution of methyl acetoacetate (2 g, 17 mmol) in THF (5 mL) was added dropwise. The mixture was stirred at 0 °C for 1 h. Then *n*-BuLi (11.7 mL, 1.6 M solution in THF, 18.7 mmol) was added dropwise at –5 °C. The mixture was stirred for 1 h while warming to room temperature and was subsequently cooled to 0 °C. Subsequently, a solution of geranyl bromide (1.84 g, 8.5 mmol) in THF (5 mL) was added dropwise. After stirring the mixture at room temperature for 3.5 h saturated aqueous NH_4Cl solution (20 mL) was added. The aqueous layer was extracted with ether (3 x 50 mL) and the organic layers were combined. The organic phase was washed with water (40 mL) and brine (40 mL), dried (Na_2SO_4) and concentrated. Flash chromatography (petroleum ether/ethyl acetate, 5:1) provided **7** (1.42 g, 66%) as a pale yellow oil. ^1H NMR (300 MHz, CDCl_3): δ 5.09–5.04 (m, 2H), 3.74 (s, 3H), 3.44 (s, 2H), 2.59–2.53 (m, 2H), 2.33–2.24 (m, 2H), 2.06–1.96 (m, 4H), 1.68 (s, 3H), 1.61 (s, 3H), 1.59 (s, 3H); ^{13}C NMR (75.5 MHz, CDCl_3): δ 202.2, 167.4, 136.5, 131.3, 123.9, 121.8, 52.3, 49.1, 43.1, 39.7, 26.6, 25.7, 17.7, 16.1. MS (EI): m/z (%) 252 (3) $[\text{M}]^+$, 234 (8), 219 (10), 209 (20), 191 (63), 177 (30), 161 (20), 151 (30), 136 (68), 129 (43), 123 (55), 121 (62), 110 (53), 109 (100), 105 (83), 101 (75), 93 (57), 81 (85), 69 (97), 67 (71), 59 (70); IR (film): $\tilde{\nu}$ 2935 (s), 2920 (s), 2870 (sh), 1749 (s), 1700 (s), 1625 (s), 1620 (sh), 1429 (s), 1375 (w), 1300 (w), 1230 (w), 1130 (w) cm^{-1} .

Methyl (6*E*)-3-hydroxy-7,11-dimethyldodeca-6,10-dienoate (8). To a solution of compound **7** (0.5 g, 1.9 mmol) in methanol (5 mL) was added sodium borohydride (0.22 g, 5.7 mmol). The mixture was stirred overnight at room temperature, and the reaction was quenched by addition of water (2 mL). The product was extracted with ether (3 x 20 mL), and the combined organic

phase was washed with brine (20 mL), dried (Na_2SO_4) and concentrated to give β -hydroxy ester **8** (0.35 g, 70%) as a colorless oil. $R_f = 0.45$ (petroleum ether/ethyl acetate 5:2). $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 5.14–5.05 (m, 2H), 2.52 (dd, $J = 3.3$ Hz, $J = 16.5$ Hz, 1H), 2.42 (dd, $J = 8.8$ Hz, $J = 16.5$ Hz, 1H), 2.17–1.96 (m, 6H), 1.68 (s, 3H), 1.62 (s, 3H), 1.59 (s, 3H); $^{13}\text{C NMR}$ (75.5 MHz, CDCl_3): δ 173.2 (C), 135.8 (C), 131.3 (C), 124.1 (CH), 123.4 (CH), 67.6 (CH), 51.8 (CH₃), 41.2 (CH₂), 39.7 (CH₂), 36.5 (CH₂), 26.7 (CH₂), 25.8 (CH₃), 24.0 (CH), 17.8 (CH₃), 16.1 (CH₃). MS (EI): m/z (%) 254 (3) $[\text{M}]^+$, 236 (20) $[\text{M}-\text{H}_2\text{O}]^+$, 221 (5), 211 (35), 193 (40), 179 (28), 167 (18), 161 (30), 153 (20), 147 (28), 135 (48), 129 (39), 119 (39), 111 (42), 107 (100), 103 (40), 93 (100), 81 (36), 69 (100), 55 (38). IR (film): $\tilde{\nu}$ 3425, 2922, 2890 (sh), 1740 (s), 1437, 1382, 1339, 1285, 1198, 1150, 1056, 933, 886, 818 cm^{-1} .

(2E)-3,7-Dimethylocta-2,6-dienal (9).²⁹ Oxalyl chloride (4.52 g, 35.6 mmol) was dissolved in dichloromethane (20 mL) and cooled to -78 °C. DMSO (5.52 mL, 77.7 mmol), dissolved in dichloromethane (15 mL), was added dropwise. After stirring at -78 °C for 10 min, a mixture of geraniol (5.0 g, 32.4 mmol) and pyridine (5.12 g, 64.8 mmol) in dichloromethane (20 mL) was added dropwise. The reaction mixture was stirred at -78 °C for 15 min, and after addition of triethylamine (22.4 mL, 0.16 mol) the reaction temperature was allowed to rise to 25 °C. The mixture was then acidified to pH 4 with 6 M hydrochloric acid. The aqueous phase was extracted with dichloromethane (50 mL). The combined organic phase was dried (Na_2SO_4) and concentrated. Flash chromatography (petroleum ether/ethyl acetate 7:1) provided geraniol **9** (4.56 g, 84 %) as a yellow oil. $R_f = 0.22$ (petroleum ether/ethyl acetate 10:1). $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 9.97 (d, $J = 8.0$ Hz, 1H), 5.90–5.84 (m, 1H), 5.09–5.01 (m, 1H), 2.23–2.17 (m, 4H), 2.16 (s, 3H), 1.67 (s, 3H), 1.59 (s, 3H); $^{13}\text{C NMR}$ (75.5 MHz, CDCl_3): δ 191.1, 163.7, 132.7, 127.3, 122.4, 40.6, 25.7, 25.6, 17.8, 17.6.

Dimethyl (3E)-2-hydroxy-4,8-dimethylnona-3,7-dienylphosphonate (10).³⁰ To a solution of dimethyl methylphosphonate (2.4 g, 19.7 mmol) in THF (40 mL) at -78 °C was added dropwise a solution of *n*-BuLi (12.3 mL, 15% solution in THF, 19.7 mmol). Then, the mixture was stirred at -78 °C for 20 min, and a solution of geraniol **9** (3.0 g, 19.7 mmol) in THF (10 mL) was added dropwise at -78 °C. The reaction mixture was stirred for 2 h while warming up. The reaction was quenched by the addition of saturated aqueous ammonium chloride solution. The aqueous phase was extracted with ether (2 x 30 mL), and the combined organic phase was dried (Na_2SO_4) and concentrated. Flash chromatography (chloroform/methanol 90:10) provided **10** (3.82 g, 70 %) as a yellow oil. $R_f = 0.65$ (chloroform/methanol 90:10). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 5.24 (dd, $J = 1.2, 8.6$ Hz, 1H), 5.07 (tt, $J = 1.2, 7.0$ Hz, 1H), 4.82–4.75 (m, 1H), 3.78 (d, $J = 3.1$ Hz, 3H), 3.75 (d, $J = 3.5$ Hz, 3H), 3.10 (d, $J = 2.7$ Hz, 1H), 2.17–1.87 (m, 6H), 1.69 (d, $J = 1.1$ Hz, 3H), 1.68 (s, 3H), 1.59 (s, 3H); $^{13}\text{C NMR}$ (75.5 MHz, CDCl_3): δ 138.6, 131.6, 123.6 (2 \times), 63.56, 52.4, 39.4 (2 \times), 26.4, 25.7, 17.8, 16.7. MS (EI): m/z (%) 276 (1) $[\text{M}]^+$, 258 (20) $[\text{M}-\text{H}_2\text{O}]^+$, 243 (30), 215 (60), 202 (50), 189 (58), 151 (73), 133 (77), 124 (100), 109 (90), 105 (78), 94 (76), 79 (83), 69 (81), 55 (57). IR (film): $\tilde{\nu}$ 3370 (bs), 2954, 2916, 2852, 1739, 1669 (sh), 1652 (w), 1447, 1375, 1243, 1185, 1035, 843, 823, 754 cm^{-1} .

Ethyl (4E)-5,9-dimethyldeca-4,8-dienoate (11). To a solution of *trans*-geraniol (5.3 mL, 30 mmol) in ether (25 mL) at $-20\text{ }^{\circ}\text{C}$ was added a solution of phosphorus tribromide (1.4 mL, 15 mmol) in ether (15 mL) within 10 min, and the reaction mixture was stirred for 4 h. The reaction was quenched with water, extracted with petroleum ether, washed in turn with water, saturated aqueous NaHCO_3 , and brine. The organic layer was dried (MgSO_4) and evaporated at $30\text{ }^{\circ}\text{C}$ to provide (*E*)-geranyl bromide (6.4 g, 99%) of as a labile yellow liquid.

To a suspension of NaH (1.44 g of 60% suspension in mineral oil, 60 mmol) in dry THF (150 mL) under argon was slowly added diethyl malonate (9.14 mL, 60 mmol) at room temperature. The resulting solution was stirred for 30 min, and a solution of geranyl bromide (4.24 g, 19.6 mmol) in THF (10 mL) was added. After stirring for 6 h the reaction mixture was quenched with saturated aqueous ammonium chloride. After addition of ether (300 mL) the organic layer was separated and washed with brine (2 x 100 mL), dried (MgSO_4), evaporated, and the bulk of the diethyl malonate removed by Kugelrohr distillation in high vacuum to afford the crude product as residue (7.90 g, max. 19.6 mmol).

A mixture of crude diester (7.90 g, max. 19.6 mmol), water (0.45 mL, 25 mmol), and lithium chloride (2.11 g, 50 mmol) in DMSO (40 mL) was heated at reflux for 4 hours. After cooling, the reaction mixture was extracted with ether/petroleum ether (1:1, 300 mL). The extract was washed with water (5 x 50 mL) and brine (5 x 50 mL), dried over MgSO_4 , evaporated to yield ester **11** (4.0 g) as yellow oil. The purity (91%) of the compound was checked by GC MS. The compound was used without purification for the next reaction. MS (EI): m/z (%) 224 (2) $[\text{M}]^+$, 209 (1) $[\text{M}-\text{CH}_3]^+$, 155 (14), 135 (57), 113 (62), 109 (86), 93 (33), 85 (73), 81 (90), 69 (100), 67 (72).

(6E)-10-Bromo-2,6-dimethyldeca-2,6-diene (12). To a solution of ester **11** (4.00 g, 17.8 mmol) in dry ether (65 mL) at $0\text{ }^{\circ}\text{C}$ was added portionwise LAH (0.68 g, 17.8 mmol), and the mixture was stirred at room temperature for 3 h. After cooling to $0\text{ }^{\circ}\text{C}$, the reaction was quenched with water (7 mL), followed by NaOH (15%, 7 mL), and the mixture was stirred for 15 min. More water (21 mL) was added, stirring was continued for 30 min and Na_2SO_4 was added. The mixture was filtered through Celite, the filter cake was extracted with diethyl ether several times, the filtrates were combined, and the solvents were evaporated to give the alcohol (3.1 g, 96 %) as a colorless oil. MS (EI): m/z (%) 182 (3) $[\text{M}]^+$, 167 (5) $[\text{M}-\text{CH}_3]^+$, 149 (22), 138 (98), 123 (68), 109 (46), 81 (97), 79 (99), 64 (100).

To a stirred solution of the alcohol (3.1 g, 17.0 mmol) in dichloromethane (40 mL) was added triethylamine (4.8 mL, 35.2 mmol) followed by dropwise addition of methanesulfonyl chloride (1.9 mL, 19.3 mmol) at $0\text{ }^{\circ}\text{C}$ within 15 min. After stirring at $0\text{ }^{\circ}\text{C}$ for 1.5 h, the reaction mixture was diluted with dichloromethane, washed rapidly with hydrochloric acid (10%, 40 mL), saturated NaHCO_3 (40 mL), and brine (40 mL). The organic phase was dried (MgSO_4) and evaporated to produce the crude mesylate (4.4 g, 99 %) as a colorless oil. MS (EI): m/z (%) 260 (1) $[\text{M}]^+$, 245 (4) $[\text{M}-\text{CH}_3]^+$, 217 (49), 149 (39), 121 (53), 107 (44), 93 (99), 79 (100), 67 (99).

The addition of anhydrous lithium bromide (4.6 g, 52.5 mmol) to a solution of the mesylate (4.4 g, 16.9 mmol) in dry THF (30 mL) at room temperature resulted in a mild exothermic reaction. The resulting suspension was stirred at room temperature for 23 h, and after dilution with ether the

organic phase was washed with water (2 x 30 mL) and brine (30 mL), dried (MgSO₄) and evaporated to provide crude bromide **12** (4.0 g, 93 %) as a pale yellow liquid. The crude product **12** without purification was immediately used for the next step. MS (EI): *m/z* (%) 244 (3) [M]⁺, 229 (4) [M-CH₃]⁺, 201 (40), 175 (13), 123 (52), 109 (37), 95 (59), 81 (39), 67 (100).

Diethyl (4E)-5,9-dimethyldeca-4,8-dienylphosphonate (13). A mixture of bromide **12** (4.0 g, 16.3 mmol) and triethyl phosphite (54 mL, 326 mmol) was stirred under argon at 150 °C for 20 h. While cooling to room temperature, triethyl phosphite was removed in high vacuum. The crude product was purified by flash chromatography (ethyl acetate/petroleum ether 1:1) to give **13** (4.1 g, 83) as a pale yellow oil. *R_f* = 0.53 (ethyl acetate). ¹H NMR (300 MHz, CDCl₃): δ 5.10–5.05 (m, 2H), 4.15–4.03 (m, 6H), 2.11–1.95 (m, 6H), 1.78–1.62 (m, 2H), 1.68 (d, *J* = 1.3 Hz, 3H), 1.60 (s, 6H), 1.32 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (75.5 MHz, CDCl₃): = 136.2, 131.2, 124.0, 122.89, 61.3 (d, *J* = 6.8 Hz), 39.7, 28.6 (d, *J* = 17.4 Hz), 26.6, 26.1, 25.7, 24.2, 22.6 (d, *J* = 5.3 Hz), 17.7, 16.6 (d, *J* = 5.3 Hz), 16.1; ³¹P (161.9 MHz, CDCl₃): δ 33.3 (s). MS (EI): *m/z* (%) 302 (6) [M]⁺, 259 (19), 233 (22), 205 (17), 177 (20), 165 (24), 152 (54), 125 (80), 109 (32), 95 (100), 81 (23), 69 (26).

Ethyl (4E)-5,9-dimethyldeca-4,8-dienylphosphonochloridoate (14). A solution of diester **13** (2.7 g, 9.0 mmol) in methanol (40 mL) was treated with 1 M aqueous potassium hydroxide (40 mL) and heated at 65 °C. The reaction course was monitored by ³¹P NMR. After 9 h the pH was adjusted to 6.5, and methanol was evaporated. The aqueous solution was acidified with 10% hydrochloric acid and extracted with ethyl acetate (3 x 50 mL). The organic layer was washed in turn with water and brine, dried (MgSO₄), and evaporated to provide the monoacid (2.4 g) as a pale yellow liquid; the purity (>83%, some heat decomposition) was checked by GC-MS. *R_f* = 0.04 (ethyl acetate). ³¹P NMR (161.9 MHz, CDCl₃): δ 27.6 (s). MS (ESI, negative mode): *m/z* 273 [M-H]⁻.

To a stirred solution of the monoacid (2.9 g, 10.8 mmol) in dichloromethane (10 mL) was added under argon *N,N*-dimethyltrimethylsilylamine (1.4 mL, 21.8 mmol). The mixture was stirred at room temperature for 2 h. The solvent was evaporated, the residue was dissolved in benzene (10 mL), and the solvent was evaporated under vacuum for 30 min. The residue was dissolved in dichloromethane (8 mL) containing 4 drops of DMF, and oxalyl chloride (1.5 mL, 18 mmol) was added under argon at 0 °C within 10 min. The solution was stirred at 0 °C for 75 min and then at room temperature for 45 min. After evaporation of the solvent the residue was dissolved in benzene, which in turn, was evaporated under high vacuum to give the unstable acid chloride **14** (3.15 g, 99%) as a labile orange oil that was immediately used without purification for the C-P coupling reaction.

Diethyl [[(4E)-5,9-dimethyldeca-4,8-dienyl](ethoxy)phosphoryl](difluoro)methylphosphonate (16). To a solution of LDA (1.5 g, 14.4 mmol) in THF (20 mL) was added dropwise a solution of diethyl difluoromethylphosphonate **15** (2.32 g, 12.0 mmol) in THF (10 mL) under argon at -78 °C within 10 min. The pale yellow solution was stirred at -78 °C for 30 min, and phosphonochloridoate **14** (3.2 g, 10.8 mmol), dissolved in THF (10 mL), was added over a period of 10 min. The solution was maintained at -78 °C for 5 h, and the reaction was quenched

with acetic acid (1.2 mL) dissolved in ether (16 mL). The mixture was allowed to warm to room temperature and was partitioned between ether and 10% HCl; the ether layer was washed with water and saturated NaHCO₃. The combined aqueous layer was extracted with dichloromethane (2 x 40 mL). The combined organic phase was dried (Na₂SO₄) and evaporated to provide an orange colored oil, which was subjected to flash chromatography (toluene/ethyl acetate/petroleum ether 1:60:90) to give **16** (2.78 g, 58 %) as a yellow liquid. $R_f = 0.37$ (petroleum ether/ethyl acetate 1:1). ¹H NMR (400 MHz, CDCl₃): δ 5.13–5.05 (m, 2H), 4.41–4.32 (m, 6H), 2.15–1.96 (m, 8H), 1.82–1.65 (m, 2H), 1.68 (s, 3H), 1.60 (s, 6H), 1.42–1.35 (m, 9H); ¹³C NMR (100.6 MHz, CDCl₃): δ 136.7, 131.3, 124.1, 122.6, 117.4 (tdd, $J = 282, 182, 104$ Hz), 65.3 (d, $J = 6.3$ Hz), 65.2 (d, $J = 6.3$ Hz), 64.4 (d, $J = 6.3$ Hz), 39.6, 28.6 (d, $J = 16.4$ Hz), 26.5, 25.5, 24.7 (d, $J = 97.8$ Hz), 20.3 (d, $J = 5.5$ Hz), 17.5, 16.4 (d, $J = 5.5$ Hz), 16.3 (d, $J = 3.9$ Hz), 16.2 (d, $J = 5.5$ Hz), 15.9; ³¹P NMR (161.9 MHz, CDCl₃): δ 41.1 (ddd, $J = 55.2, 71.0, 78.0$ Hz), 4.5 (td, $J = 55.2, 85.4$ Hz); ¹⁹F NMR (376.3 MHz, CDCl₃): δ -122.4 (ddd, $J = 78.0, 85.0, 371.6$ Hz), -124.1 (ddd, $J = 71.0, 85.4, 371.6$ Hz). MS (EI): m/z (%) 444 (3) [M]⁺, 188 (42), 109 (46), 95 (100), 69 (46). **(2E,6E)-3,7,11-Trimethyldodeca-2,6,10-trienyl acetate (17)**.²¹ Acetic anhydride (0.73 mL, 7.6 mmol) was added to a solution of *E,E*-farnesol (1.0 g, 4.4 mmol) in pyridine (0.71 mL, 8.9 mmol). The mixture was stirred over night at room temperature and diluted with ether (50 mL). The organic layer was washed with water (30 mL), 2 M hydrochloric acid (2 x 30 mL), water (30 mL), and brine (30 mL), dried (Na₂SO₄), and concentrated. Flash chromatography (petroleum ether/ethyl acetate 10:1) provided **17** (0.89 g, 75 %) as a colorless oil. $R_f = 0.63$ (petroleum ether/ethyl acetate 10:1). ¹H NMR (300 MHz, CDCl₃): δ 5.39 (m, 1H), 5.20 (m, 2H), 4.75 (d, $J = 8.0$ Hz, 2H), 2.02 (m, 8H), 2.01 (s, 3H), 1.72 (s, 3H), 1.71 (s, 3H), 1.70 (s, 3H), 1.69 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 171.1, 138.7, 138.6, 133.9, 122.5, 121.9, 121.7, 62.9, 40.5, 40.2, 25.3, 24.3, 24.0, 19.3, 17.4, 17.2, 16.9.

(2E,6E)-10-Bromo-11-hydroxy-3,7,11-trimethyldodeca-2,6-dienyl acetate (18).²¹ To a stirred solution of *E,E*-farnesyl acetate **17** (2.1 g, 7.9 mmol) in 1,2-dimethoxyethane (16 mL) and water (10 mL) at 0 °C was added within 30 min a solution of *N*-bromosuccinimide (1.48 g, 8.3 mmol) in 1,2-dimethoxyethane (25 mL). The mixture was stirred at 0 °C for 4 h and was then poured into brine (40 mL) followed by extraction with ether (3 x 40 mL). The combined organic layer was washed with brine (40 mL), dried (Na₂SO₄) and concentrated *in vacuo* to give crude **18** (2.82 g) as a pale yellow oil. $R_f = 0.16$ (petroleum ether/ethyl acetate 10:1). ¹H NMR (300 MHz, CDCl₃): δ 5.34 (dt, $J = 1.2, 7.0$ Hz, 1H), 5.19 (dd, $J = 5.9, 6.8$ Hz, 1H), 4.59 (d, $J = 7.0$ Hz, 2H), 3.96 (dd, $J = 1.9, 11.4$ Hz, 1H), 2.35–2.28 (m, 2H), 2.16–2.07 (m, 2H), 2.05 (s, 3H), 2.01–1.93 (m, 1H), 1.84–1.73 (m, 1H), 1.70 (s, 3H), 1.60 (s, 3H), 1.35 (s, 3H), 1.34 (s, 3H); ¹³C NMR (75.5 MHz, CDCl₃): δ 170.9, 141.8, 133.4, 125.2, 118.3, 70.6, 61.4, 39.4, 38.1, 32.0, 26.6, 26.2, 25.9, 21.1, 16.5, 15.9.

(2E,6E)-9-(3,3-Dimethyloxiran-2-yl)-3,7-dimethylnona-2,6-dien-1-ol (19).²¹ Bromohydrin **18** (0.35 g, 0.97 mmol) was dissolved in methanol (10 mL), and to the solution was added potassium carbonate (0.40 g, 2.91 mmol). The mixture was stirred over night at room temperature, filtered through Celite, and the filtrate was concentrated *in vacuo*. The residue was

diluted with brine (10 mL) and extracted with ether (3 x 10 mL). The combined ether layer was washed with brine (10 mL), dried (Na_2SO_4), and concentrated *in vacuo* to give **19** (0.14 g, 63 %) as a colorless oil. $R_f = 0.49$ (petroleum ether/ethyl acetate 2:1). ^1H NMR (400 MHz, CDCl_3): δ 5.40 (t, $J = 7.0$ Hz, 1H), 5.15 (t, $J = 7.0$ Hz, 1H), 4.13 (d, $J = 7.0$ Hz, 2H), 2.70 (t, $J = 6.0$ Hz, 1H), 2.15–2.02 (m, 6H), 1.67 (s, 3H), 1.62 (s, 3H), 1.55–1.52 (m, 2H), 1.30 (s, 3H), 1.26 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 139.41, 134.49, 124.71, 123.79, 64.53, 59.55, 58.80, 39.80, 36.74, 27.68, 26.57, 25.31, 19.25, 16.70, 16.45.

(2E,6E)-3,7,11-Trimethyldodeca-2,6-diene-1,10,11-triol (20).²² To a stirred solution of epoxide **19** (0.1 g, 0.4 mmol) in a mixture of water (2.5 mL) and THF (5 mL) were added 4 drops of 70% aqueous perchloric acid. After 4 h the mixture was extracted with ether (3 x 10 mL), and the combined organic layer was washed with water (10 mL) and brine (10 mL), dried (Na_2SO_4), and concentrated *in vacuo* to give **20** (78 mg, 73 %) as a pale yellow oil. $R_f = 0.16$ (petroleum ether/ethyl acetate 1:1). ^1H NMR (300 MHz, CDCl_3): δ 5.38 (dd, $J = 5.5$, 6.8 Hz, 1H), 5.16 (t, $J = 6.1$ Hz, 1H), 4.13 (d, $J = 6.6$ Hz, 2H), 3.36 (dd, $J = 1.9$, 10.4 Hz, 1H), 2.39–2.28 (m, 2H), 2.22–2.04 (m, 4H), 1.64 (s, 3H), 1.61 (s, 3H), 1.46–1.39 (m, 1H), 1.37–1.32 (m, 1H), 1.17 (s, 3H), 1.14 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ 138.6, 134.9, 125.0, 124.0, 77.6, 73.0, 59.3, 39.3, 36.6, 28.9, 26.4, 25.6, 23.3, 15.9, 15.8.

(6E,10E)-12-Chloro-2,6,10-trimethyldodeca-6,10-diene-2,3-diol (21). *N*-Chlorosuccinimide (0.08 g, 0.64 mmol) was dissolved in dichloromethane (40 mL) and cooled to -30 °C. To the cooled, well stirred, now heterogeneous mixture dimethyl sulfide (51 μL , 0.70 mmol) was added dropwise. The mixture was briefly allowed to warm to 0 °C before the temperature was lowered to -40 °C. A solution of the **20** (0.15 g, 0.58 mmol) in dichloromethane (5 mL) was added through a syringe to the milky white suspension within 3 min. The reaction was slowly (1 h) allowed to warm to 0 °C and maintained at this temperature for 1 h. During this period, the mixture became a clear colorless solution. The ice bath was removed, and the mixture was stirred at room temperature for 15 min before it was poured into cold brine (25 mL) in a separatory funnel. The aqueous layer was extracted with pentane (2 x 20 mL). To the combined organic layer was added pentane (20 mL), and this solution was washed with cold brine (2 x 10 mL), dried (Na_2SO_4), concentrated *in vacuo* to provide chloride **21** (0.16 g, 98 %) as a pale yellow oil. ^1H NMR (300 MHz, CDCl_3): δ 5.42 (dt, $J = 1.1$, 7.9 Hz, 1H), 5.15 (dd, $J = 1.4$, 6.9 Hz, 1H), 4.09 (d, $J = 7.9$ Hz, 2H), 3.34 (dd, $J = 1.9$, 10.4 Hz, 1H), 2.26–2.01 (m, 6H), 1.72 (s, 3H), 1.61 (s, 3H), 1.58–1.54 (m, 1H), 1.37–1.32 (m, 1H), 1.19 (s, 3H), 1.15 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ 142.4, 135.3, 124.0, 120.4, 78.2, 41.2, 39.3, 36.7, 30.4, 29.7, 26.5, 26., 23.3, 16.1.

Enzyme inhibition assay. The standard 1mM assay contained in a final volume of 100 μL : 10 μL of a 10 mM *p*-hydroxybenzoate solution; 10 μL organic soluble inhibitor in DMSO (blank, or 0.5 mM, or 1 mM, or 2 mM, or 5 mM, or 10 mM solutions of potential inhibitors, obtained by a dilution series from a 10 mM solution), or 10 μL water soluble inhibitor in Tris/HCl buffer (pH 7.8, blank, or 0.5 mM, or 1 mM, or 2 mM, or 5 mM, or 10 mM solutions of potential inhibitors, obtained by a dilution series from a 10 mM solution); 10 μL of a 0.05 M MgCl_2 solution; 10 μL

of a 10 mM solution of geranyl diphosphate and 50 μ L of enzyme²³ in 50 mM Tris/HCl, 10 mM DTT buffer, pH 7.8. Incubation was done under shaking at 37 °C for 2 h. The reaction was quenched by the addition of 10 μ L 2% aqueous formic acid solution. Products were extracted with ethyl acetate (0.5 mL) containing *p*-hydroxybiphenyl (50 μ M) as internal HPLC-standard. Ethyl acetate was then removed *in vacuo* and the remainder was dissolved in methanol (100 μ L). The samples were then analyzed for the formation of GHB by HPLC.

Acknowledgements

The pALMU3 plasmid was kindly provided by Prof. L. Heide (Tübingen). We would like to thank Prof. M. Pietzsch and Dr. T. Hertel (Martin-Luther-Universität Halle-Wittenberg) for their support with optimizing fermentation, enzyme preparation, and for invaluable discussions. We thank the state of Saxony-Anhalt for support as part of the HWP-program.

References

1. (a) Poulter, C. D.; Rilling, H. C. *Acc.Chem. Res.* **1978**, *11*, 307. (b) Poulter, C. D.; Mash, E. A.; Argyle, J. C.; Muscio, O. J.; Rilling, H. C. *J. Am. Chem. Soc.* **1979**, *101*, 6761.
2. Ashby, M. N.; Edwards, P. A. *J. Biol. Chem.* **1990**, *265*, 13157.
3. Caillet, J.; Droogmans, L.; *J. Bacteriol* **1988**, *170*, 4147.
4. (a) Stöber, P.; Schelhaas, M.; Nägele, E.; Hagenbuch, P.; Rétey, J.; Waldmann, H. *Bioorg. Med. Chem.* **1997**, *5*, 75. (b) Mayer, M. P.; Prestwich, G. D.; Dolence, J. M.; Bond, P. D.; Wu, H. Y.; Poulter, C. D. *Gene* **1993**, *132*, 41.
5. Shineberg, B.; Yong, I. G. *Biochemistry* **1976**, *15*, 2754.
6. (a) Wessjohann, L.; Sontag, B. *Angew. Chem.* **1996**, *108*, 1821. *Angew. Chem., Int. Ed.* **1996**, *35*, 1697. (b) Wessjohann, L. A.; Sontag, B.; Dessoy, M. A. In *Bioorganic Chemistry*; Diederichsen, U.; Lindhorst, T. K.; Westermann, B.; Wessjohann, L. A., Eds.; Wiley-VCH: Weinheim, 1999; pp 79–88. (c) Wessjohann, L.; Sontag, B. *GIT Labor-Fachzeitschrift* **1998**, *42*, 229.
7. Singh, S. B.; Zink, D. L.; Liesch, J. M.; Goetz, M. A.; Jenkins, R. G.; Nallin-Omstead, M.; Silverman, K. C.; Bills, G. F.; Mosley, R. T.; Gibbs, J. B.; Albers-Schonberg, G.; Lingham, R. B. *Tetrahedron* **1993**, *49*, 5917.
8. Corey, E. J.; Volante, R. P. *J. Am. Chem. Soc.* **1976**, *98*, 1291.
9. McClard, R. W.; Fujita, T. S.; Stremmer, K. E.; Poulter, C. D. *J. Am. Chem. Soc.* **1987**, *109*, 5544.
10. Stremmer, K. E.; Poulter, C. D. *J. Am. Chem. Soc.* **1987**, *109*, 5542.
11. Holstein, S. A.; Cermak, D. M.; Wiemer, D. F.; Lewis, K.; Hohl, R. J. *Bioorg. Med. Chem.* **1998**, *6*, 687.

12. Fulhorst, M.; Wessjohann, L. manuscript in preparation.
13. Kang, M. S.; Stermerick, D. M.; Zwolshen, J. H.; Harry, S.; Sunkara, P. S.; Harrison, B. L. *Biochem. Biophys. Res. Com.* **1995**, *217*, 245.
14. Biller, S. A.; Forster, C. *Tetrahedron* **1990**, *46*, 6645.
15. Cermak, D. M.; Wiemer, D. F.; Lewis, K.; Hohl, R. *Bioorg. Med. Chem.* **2000**, *8*, 2729.
16. Bhattacharya, A. K.; Thyagarajan, G. *Chem. Rev.* **1981**, *81*, 415.
17. Bhongle, N. N.; Notter, R. H.; Turcotte, J. G. *Synth. Commun.* **1987**, *17*, 1071.
18. Obayashi, M.; Ito, E.; Matsui, K.; Kondo, K. *Tetrahedron Lett.* **1982**, *23*, 2323.
19. van Tamelen, E. E.; Sharpless, K. B. *Tetrahedron Lett.* **1967**, 2655.
20. Hanzlik, R. P. *Org. Synth.* **1977**, *56*, 112.
21. Sakai, T.; Mori, K. *Agric. Biol. Chem.* **1986**, *50*, 177.
22. Suzuki, Y.; Marumo, S. *Tetrahedron Lett.* **1972**, *19*, 1887.
23. Davisson, V. J.; Woodside, A. B.; Neal, T. R.; Stremler, K. E.; Muehlbacher, M.; Poulter, C. D. *J. Org. Chem.* **1986**, *51*, 4768.
24. (a) Heide, L.; Melzer, M.; Siebert, M.; Bechthold, A.; Schröder, J.; Severin, K. *J. Bacteriol.* **1993**, *175*, 5728. (b) Melzer, M.; Heide, L. *Biochim. Biophys. Acta* **1994**, *1212*, 93.
25. Khmel'nitsky, Y. L.; Rich, J. O. *Curr. Opin. Chem. Biol.* **1999**, *3*, 47.
26. (a) Blachburn, G. M.; England, D. A.; Kolkman, F. *J. Chem. Soc., Chem. Commun.* **1981**, 930. (b) Blachburn, G. M.; Kent, D. E.; Kolkman, F. *J. Chem. Soc., Chem. Commun.* **1981**, 1188. (c) Blachburn, G. M.; Eckstein, F.; Kent, D. E.; Perree, T. D. *Nucleosides Nucleotides* **1985**, *4*, 165. (d) Phan, R. M.; Poulter, C. D. *J. Org. Chem.* **2001**, *66*, 6705.
27. Fulhorst, M. *Prenyltransferases as Potential Biocatalysts*. Doctoral Dissertation,; L. A. Wessjohann, Ed.; Martin-Luther-Universität Halle-Wittenberg: Halle (Saale), 2003.
28. Corey, E. J.; Desai, M. C. *Tetrahedron Lett.* **1985**, *26*, 3535.
29. (a) Biller, S. A.; Forster, C.; Gordon, E. M.; Harrity, T.; Scott, W. A.; Ciosek, C. P. *J. Med. Chem.* **1988**, *31*, 1869. (b) Fumoto, Y.; Eguchi, T.; Uno, H.; Ono, N. *J. Org. Chem.* **1999**, *64*, 6518.
30. Dessoy, M. A. *Synthesis and Enzymatic Coupling of Prenyldiphosphates and Benzoates*; Doctoral Dissertation, L. A. Wessjohann, Ed.; Martin-Luther-Universität: Halle-Wittenberg, Halle (Saale), 2003.